Search

Schizophrenia (SCZ) is a multifactorial mental illness, thus it will be beneficial for exploring this disease using multimodal data, including functional magnetic resonance imaging (fMRI), genes, and the gut microbiome. Previous studies reported combining multimodal data can offer complementary information for better depicting the abnormalities of SCZ. However, the existing multimodal-based methods have multiple limitations. First, most approaches cannot fully use the relationships among different modalities for the downstream tasks. Second, representing multimodal data by the modality-common and modality-specific components can improve the performance of multimodal analysis but often be ignored. Third, most methods conduct the model for classification or regression, thus a unified model is needed for finishing these tasks simultaneously. To this end, a multi-loss disentangled generative-discriminative learning (MDGDL) model was developed to tackle these issues. Specifically, using disentangled learning method, the genes and gut microbial biomarkers were represented and separated into two modality-specific vectors and one modality-common vector. Then, a generative-discriminative framework was introduced to uncover the relationships between fMRI features and these three latent vectors, further producing the attentive vectors, which can help fMRI features for the downstream tasks. To validate the performance of MDGDL, an SCZ classification task and a cognitive score regression task were conducted. Results showed the MDGDL achieved superior performance and identified the most important multimodal biomarkers for the SCZ. Our proposed model could be a supplementary approach for multimodal data analysis. Based on this method, we could analyze the SCZ by combining multimodal data, and further obtain some interesting findings.

The intricate processes of microbiota-gut-brain communication in modulating human cognition and emotion, especially in the context of mood disorders, have remained elusive. Here we performed faecal metagenomic, serum metabolomics and neuroimaging studies on a cohort of 109 unmedicated patients with depressed bipolar disorder (BD) patients and 40 healthy controls (HCs) to characterise the microbial-gut-brain axis in BD. Across over 12,000 measured metabolic features, we observed a large discrepancy (73.54%) in the serum metabolome between BD patients and HCs, spotting differentially abundant microbial-derived neuroactive metabolites including multiple B-vitamins, kynurenic acid, gamma-aminobutyric acid and short-chain fatty acids. These metabolites could be linked to the abundance of gut microbiota presented with corresponding biosynthetic potentials, including Akkermansia muciniphila, Citrobacter spp. (Citrobacter freundiiand Citrobacter werkmanii), Phascolarctobacterium spp., Yersinia spp. (Yersinia frederikseniiand Yersinia aleksiciae), Enterobacter spp. (Enterobacter cloacaeand Enterobacter kobei) and Flavobacterium spp. Based on functional neuroimaging, BD-related neuroactive microbes and metabolites were discovered as potential markers associated with BD-typical features of functional connectivity of brain networks, hinting at aberrant cognitive function, emotion regulation, and interoception. Our study combines gut microbiota and neuroactive metabolites with brain functional connectivity, thereby revealing potential signalling pathways from the microbiota to the gut and the brain, which may have a role in the pathophysiology of BD.